A case report attributed an unexplained coma to benzodiazepine exposure using several clinical observations. Its urine result and unusual MRI appearance did not identify a specific ingested product or dose.
The patient was unarousable with obstructive apnea and had bilateral globus pallidus signal changes on MRI. A urine immunoassay was strongly positive for benzodiazepines. Neither the patient nor relatives could identify the exposure source.
Consciousness improved markedly after flumazenil, and the patient subsequently recovered without reported neurologic symptoms at follow-up.
The clinical response strengthened the authors’ interpretation of a benzodiazepine contribution. The urine class assay was not a measured blood concentration of an identified parent drug. Its reported numerical value cannot be treated as an ingested amount.
A single unusual imaging finding also does not establish a specific MRI signature of benzodiazepine poisoning or exclude every alternative mechanism.
Describe the converging clinical evidence and the unresolved identity, timing, and source of exposure. This case does not justify administering an antagonist in every unexplained coma or applying its imaging appearance as a diagnostic rule. Individual assessment of a mixed or unknown exposure remains necessary.
Original analysis of the supplied journal article, identified as PMC3439771.